When Miami Dade-County leaders set out to quantify the extent of COVID-19 infection in the county, they tapped researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine to lead this effort.
Erin Kobetz, Ph.D., M.P.H., and Alberto Caban-Martinez, D.O., Ph.D., M.P.H., are the director and deputy director of Sylvester’s Firefighter Cancer Initiative. They’re applying their expertise at assessing the burden of cancer among first responders to providing a better picture of how many people in Miami-Dade have been infected with the novel coronavirus.
A pulmonologist with the University of Miami Health System and the Miller School of Medicine has initiated a new therapy for the first time in a patient with novel coronavirus COVID-19 diagnosis. The treatment has the potential to delay the need for a ventilator.
The COVID-19 pandemic is, at least temporarily, changing how everyone lives. Caution has become the operative word as people adjust their daily habits to maintain protective distance. The phrase “out of an abundance of caution” is now imprinted into the national consciousness.
One of the few manufacturers in the world that meets the high-quality research standards in the U.S. and Europe for medicinal cannabinoid (CBD) is collaborating with University of Miami Miller School of Medicine researchers, providing the company’s product for groundbreaking studies.
As the COVID-19 pandemic unfolds, inaccurate medical information has flooded social media and other channels. One potentially lethal example is that patients who take renin-angiotensin system (RAS) blockers, particularly angiotensin II type 1 receptor blockers (ARBs), may be more susceptible to the virus.
Biomedical researchers at the University of Miami Miller School of Medicine are developing a COVID-19 point-of-care diagnostic test in collaboration with biopharmaceutical company Heat Biologics, Inc.